Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
March 21 2024 - 2:00AM
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate
in Multiple Events at the 24th World Vaccine Congress in Washington
D.C.
Saint-Herblain (France), March 21, 2024 –
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, today announced it will present on its single-shot
chikungunya vaccine, IXCHIQ®, moderate a roundtable on the Zika and
chikungunya viruses, and participate in a panel discussion on
efforts to eradicate chikungunya at the 24th World Vaccine
Congress, which will take place between April 1-4, 2024 at the
Walter E. Washington convention center in Washington, D.C. The
Company will have a display in the exhibit area of the congress at
booth #433.
On April 2, Valneva’s Head of Global Market
Access & Value Evidence, Gerard Vondeling, and Market Access
Manager, Adrianne de Roo, will moderate the “Public Health
Priorities: The Emerging Threats of Zika and Chikungunya”
interactive roundtable. There will be two sessions, from 11:40 to
12:20 EST and again from 12:30 to 1:10pm EST.
In the evening of April 2, Valneva will attend
the Vaccine Industry Excellence Awards ceremony, where it is a
finalist for the Best Prophylactic Vaccine award for IXCHIQ®, the
world’s first and only chikungunya vaccine to address this unmet
medical need. IXCHIQ®, which is approved in the United States
(U.S.), was recently recommended by the U.S. Advisory Committee on
Immunization Practices (ACIP)1 and these recommendations were
adopted by the Centers for Disease Control and Prevention (CDC)2.
Additionally, Valneva CEO Thomas Lingelbach will present the Best
Production / Process Development award at the event.
On April 3 at 9:40am EST, Valneva’s VP of
Clinical Development, Susanne Eder-Lingelbach, will present
“Antibody persistence of a single-dose live-attenuated chikungunya
virus vaccine (VLA1553) in adults.”
Also on April 3, at 12:25pm EST, Valneva’s Chief
Medical Officer, Dr. Juan Carlos Jaramillo, will take part in the
“Vaccine Development and Efforts towards Eradicating Chikungunya”
panel discussion alongside Timothy Endy, Disease X and CHIKV
Project Leader at the Coalition for Epidemic Preparedness
Innovations (CEPI), Thais Dos Santos, Advisor, Surveillance and
Control of Arboviral Diseases at the Pan American Health
Organization (PAHO) and moderated by Sushant Sahastrabuddhe, Deputy
Director General of the International Vaccine Institute (IVI).
Additionally, at 5:40pm EST on April 3, Eduardo
Forleo-Neto, VP, Vaccine Clinical Research & Development at
Pfizer, will present “6-Valent, OspA-based Lyme Disease Vaccine
(VLA15) - Clinical Development Overview,” on Pfizer and Valneva’s
Lyme disease vaccine candidate. VLA15 is currently in Phase 3
clinical development and partnered with Pfizer for this study and
global commercialization. Recruitment completion for the study was
announced in December 20233.
About
IXCHIQ®In the U.S.,
IXCHIQ® is a live-attenuated vaccine indicated for
the prevention of disease caused by chikungunya virus (CHIKV) in
individuals 18 years of age and older who are at increased risk of
exposure to CHIKV. As for all products approved under FDA’s
accelerated approval pathway, continued approval for this
indication is contingent upon verification and description of
clinical benefit in confirmatory studies.
Please click here for
full Prescribing Information for
IXCHIQ®.
About VLA15There are currently
no approved human vaccines for Lyme disease, and VLA15 is the most
advanced Lyme disease vaccine candidate currently in clinical
development, with two Phase 3 trials in progress (VALOR -
NCT05477524 and NCT05634811). This investigational multivalent
protein subunit vaccine uses an established mechanism of action for
a Lyme disease vaccine that targets the outer surface protein A
(OspA) of Borrelia burgdorferi, the bacteria that cause Lyme
disease. OspA is a surface protein expressed by the bacteria when
present in a tick. Blocking OspA inhibits the bacterium’s ability
to leave the tick and infect humans. The vaccine candidate covers
the six most common OspA serotypes expressed by the Borrelia
burgdorferi sensu lato species that are prevalent in North America
and Europe. VLA15 is an alum-adjuvanted formulation, administered
intramuscularly and has demonstrated a strong immune response as
well as satisfactory safety profile in pre-clinical and clinical
trials so far.
About Valneva SEWe are a
specialty vaccine company that develops, manufactures, and
commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple
vaccine modalities, focused on providing either first-, best- or
only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market three proprietary travel vaccines as well as certain
third-party vaccines leveraging our established commercial
infrastructure.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the only Lyme disease vaccine candidate in advanced
clinical development, which is partnered with Pfizer, as well as
vaccine candidates against the Zika virus and other global public
health threats.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP,
Global Communications and European Investor RelationsM +33 (0)6
4516 7099communications@valneva.com |
Joshua
Drumm, Ph.D.VP, Global Investor Relations M +001 917 815
4520joshua.drumm@valneva.com |
|
|
1 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s
Single-Dose Chikungunya Vaccine IXCHIQ® - Valneva2 ACIP Vaccine
Recommendations and Schedules | CDC3 Pfizer and Valneva Complete
Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine
Candidate, VLA15 - Valneva
- 2024_03_21_VLA_WVC_PR_EN_Final
Valneva (TG:AYJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Valneva (TG:AYJ)
Historical Stock Chart
From Jul 2023 to Jul 2024